Karyopharm Therapeutics (NASDAQ:KPTI) Rating Lowered to “Hold” at StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Wednesday.

A number of other research firms have also issued reports on KPTI. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Robert W. Baird reduced their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $0.88 on Wednesday. The business’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $0.91. The firm has a market capitalization of $109.99 million, a price-to-earnings ratio of -0.75 and a beta of 0.16. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to analysts’ expectations of $37.86 million. During the same period in the previous year, the company posted ($0.30) EPS. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.95 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics during the second quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the second quarter worth about $143,000. Acadian Asset Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $167,000. Exchange Traded Concepts LLC increased its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $494,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).